Supported Approaches
PREVENT supports these approaches to prevention:
- Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents)
- Chemoprevention (e.g., novel mechanisms, novel agents, anti-inflammatory approaches, drug repurposing, toxicity reduction strategies by dose and scheduling optimization, alternative routes of drug administration or combination regimens)
- Clinically translatable biomarkers of tumor progression and/or prevention efficacy
PREVENT Cycles 1 through 21
A total of 120 projects have been implemented: 72 chemoprevention projects, 39 immunoprevention projects, and 9 biomarker projects. There are a total of 40 OPEN projects 80 COMPLETED projects.
Open Projects
Jump to: Bladder | Breast | Colon | Lung | Ovary | Pancreas | Prostate | Other Cancers
| Cancer Type | Project Type | Project Title | Application Principal Investigator (PI) | Applicant PI's Institution | NIH_RePORT_LINK |
|---|---|---|---|---|---|
| Bladder | Chemoprevention | Preclinical Development of Newly Formulated Chemopreventive Agent 4-methylumbelliferone Prodrug | Lokeshwar, Vinata, PhD | Augusta University | 261201500036I-0-26100010-1 |
| Chemoprevention | Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) When Administered in Combination | Grubbs, Clinton J., PhD | University of Alabama at Birmingham | 75N91019D00020-0-759102000003-1 | |
| Chemoprevention | Evaluation of Two Different Classes of compounds (STAT3 Inhibitors and SERMs) for the Prevention of Urinary Bladder Cancer | Grubbs, Clinton J., PhD | University of Alabama at Birmingham | 75N91019D00020-0-759102000005-1 | |
| Chemoprevention | Bladder Cancer Chemoprevention Using AR Inhibitor Apalutamide | Madka, Venkateshwar, PhD | University of Oklahoma Health Sciences | 75N91019D00020-0-759102200002-1 | |
| Immunoprevention | Further Development of Multi-Antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer | Disis, Mary (Nora) L., MD, MS | University of Washington | 261201500036I-0-26100011-1 | |
| Breast | Chemoprevention | RANK Ligand Inhibition: A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer | Lindeman, Geoffrey, PhD, FRACP, MBBS | Walter and Eliza Hall Institute of Medical Research | 261201500018I-0-26100009-1 |
| Chemoprevention | Targeting the RXR Pathway for the Prevention of Triple Negative Breast Cancer | Mazumdar, Abhijit, PhD | MD Anderson Cancer Center, University of Texas | 261201500018I-0-26100008-1 | |
| Chemoprevention | Use of Rosemary Extract/Carnosic Acid for Prevention of Ductal Carcinoma in situ | Behbod, Fariba, PharmD, PhD | University of Kansas Medical Center | 75N91019D00016-0-759102000001-1 | |
| Chemoprevention | Pre-clinical Assessment and IND for AFPep: Prevention of Breast Cancer | Andersen, Thomas T., PhD | Albany Medical College | 75N91019D00012-0-759102100001-1 | |
| Chemoprevention | Targeting the PARP Pathway for the Prevention of Breast Cancer | Brown, Powel H., MD, PhD | MD Anderson Cancer Center, University of Texas | 75N91019D00021-0-759102200001-1 | |
| Immunoprevention | Evaluating Whether Concurrent 9cUAB30 Rexinoic Acid Receptor Agonist and HER2-IGFBP2-IGF1R Vaccine Can Enhance Treatment of Ductal Carcinoma In Situ and Prevention of Invasive Breast Cancer | Stanton, Sasha E, MD, PhD | University of Washington | 261201500036I-0-26100009-2 | |
| Immunoprevention | Cancer Prevention by Vaccination Against Induced Antigens | Hanash, Samir M., MD, PhD | MD Anderson Cancer Center | 75N91019D00021-0-759101900132-1 | |
| Immunoprevention | A Novel Multi-antigen Vaccine (TNBCvax) to Prevent Triple Negative Breast Cancer | You, Ming, MD, PhD | Houston Methodist Research Institute | 75N91019D00020-0-759102100003-1 | |
| Colon | Chemoprevention | A Novel Non-COX Inhibitory Sulindac Derivative for Colorectal Cancer Chemoprevention with Selective PDE10 and Wnt/β-Catenin Inhibitory Activity | Piazza, Gary A., PhD | University of South Alabama Mitchell Cancer Institute | 261201500032I-0-26100003-1 |
| Chemoprevention | LFA-9 (mPGES-1/5-LOX inhibitor): Preclinical Studies to Support a Clinical Trial | Rao, Chinthalapally V., PhD | University of Oklahoma Health Sciences | 261201500024I-0-26100005-1 | |
| Chemoprevention | TP-252: A Longer Acting Eicosapentaenoic Acid (EPA) Analogue for Colorectal Cancer Chemoprevention | Rosenberg, Daniel W., PhD | University of Connecticut School of Medicine | 75N91019D00019-0-759101900132-1 | |
| Chemoprevention | Preventing Colorectal Cancer Using TRAIL Inducing ONC201 Alone or in Combination with NSAID | Rao, Chinthalapally V., PhD | University of Oklahoma Health Sciences | 75N91019D00020-0-759102000004-2 | |
| Chemoprevention | Targeting STAT3 to Prevent Colorectal Cancer Secondary to Inflammatory Bowel Disease | Tweardy, David J., MD | MD Anderson Cancer Center, University of Texas | 75N91019D00021-0-759102100002-1 | |
| Chemoprevention | Next Generation GP130/IL-6/STAT3 Inhibitors for the Prevention of Malignant Mesothelioma and Colitis-associated Colorectal Cancer | Clapper, Margie L., PhD | Fox Chase Cancer Center | 75N91019D00022-0-759102200002-1 | |
| Chemoprevention | Preventing FAP-CRC using rLon Protease in PIRC Rat Model | Rao, Chinthalapally V., PhD | University of Oklahoma Health Sciences | 75N91019D00020-0-759102200001-1 | |
| Immunoprevention | Frameshift peptide Vaccine for the Prevention of Lynch Syndrome-associated Gastrointestinal Cancer | Lipkin, Steven M., MD, PhD, FACMG | Weill Cornell Medicine | 261201500039I-0-26100005-1 | |
| Immunoprevention | Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability | Lipkin, Steven M., MD, PhD, FACMG | Weill Cornell Medicine | 75N91019D00025-0-759101900130-1 | |
| Immunoprevention | Further Development of Colovac, a Multi-antigen Multi-peptide Vaccine, for Colon Cancer Prevention | Disis, Mary (Nora) L., MD, MS | University of Washington | 75N91019D00019-0-759101900131-1 | |
| Immunoprevention | Anti-Fusobacterium nucelatum Vaccine for Colorectal Cancer Immunoprevention | Lipkin, Steven M., MD, PhD, FACMG | Weill Cornell Medicine | 261201500039I-0-26100004-1 | |
| Immunoprevention | Prevention of Colorectal Cancer with iPSC-based Vaccine | Wu, Joseph, MD, PhD | Stanford University | 75N91019D00021-0-759102100001-1 | |
| Immunoprevention | Vaccines Against Fusobacterium for FAP- and Lynch Syndrome-associated Colorectal Cancer Immunoprevention | Lipkin, Steven M., MD, PhD, FACMG | Weill Cornell Medicine | 75N91019D00022-0-759102200001-1 | |
| Lung | Chemoprevention | Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung and Breast Cancer | Aldaz, C. Marcelo, MD, PhD | MD Anderson Cancer Center | 75N91019D00021-0-759101900131-1 |
| Chemoprevention | Chemoprevention with Aerosolized Let-7 microRNA in Mouse Models of Non-Small Cell Lung Cancer (Adenocarcinoma and Squamous Cell Carcinoma) | You, Ming, MD, PhD | Houston Methodist Research Institute (formerly at MCW) | 75N91019D00020-0-759101900130-1 | |
| Chemoprevention | Preventing Lung Cancer by Targeting Activated STAT3 | Siegfried, Jill M., PhD | University of Minnesota | 75N91019D00022-0-759102000001-1 | |
| Immunoprevention | Lowering the risk of lung and other cancers in high-risk smokers using an anti-nicotine human mAb for smoking cessation | Kalnik, Matthew W., PhD | Antidote Therapeutics, Inc. | NA | |
| Immunoprevention | EGFR and KRAS Vaccine to Prevent Lung Cancer | You, Ming, MD, PhD | Houston Methodist Research Institute (formerly at MCW) | 75N91019D00020-0-759102000002-1 | |
| Immunoprevention | Potentiation of a Multi-antigen Lung Cancer Vaccine with CA170 | You, Ming, MD, PhD | Houston Methodist Research Institute | 75N91019D00020-0-759102100001-1 | |
| Ovary | Immunoprevention | Primary Immunoprevention of Human Epithelial Ovarian Carcinoma (EOC) | Tuohy, Vincent K, PhD | Cleveland Clinic | 75N91019D00020-0-759102100002-1 |
| Pancreas | Biomarkers | Evaluation of Real-time Metabolic Imaging Biomarkers for Detection of Pancreatic Premalignant Lesions | Bhattacharya, Pratip PhD | MD Anderson | 75N91019D00021-0-759102100003-1 |
| Immunoprevention | Further Testing of a Multi-peptide KRAS Vaccine for Pancreatic Cancer Prevention | You, Ming, MD, PhD | Houston Methodist Research Institute (formerly at MCW) | 75N91019D00020-0-759102000001-1 | |
| Immunoprevention | Preclinical Testing of CD73 Inhibitors for Pancreatic Cancer Immunoprevention | Bailey, Jennifer M., PhD | University of Texas Health Science Center Houston | 75N91019D00021-0-759102000002-1 | |
| Prostate | Immunoprevention | Preclinical Development of an RNA Vaccine for Immunoprevention of Prostate Cancer | Erasmus, Jesse, PhD | HDT Bio Corp | 75N91019D00012-0-759102000001-1 |
| Other, Liver | Chemoprevention | Targeting STAT3 to Prevent Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH) | Tweardy, David J., MD | MD Anderson Cancer Center | 75N91019D00021-0-759102000001-1 |
| Other, Skin | Chemoprevention | A Dual AKT/PDPK1 Inhibitor for Actinic Keratosis and Skin Cancer Prevention | Kirkpatrick, Lynn D, PhD | PHusis Therapeutics | 261201500026I-0-26100003-1 |
| Chemoprevention | Topical Resatorvid for Nonmelanoma Skin Cancer Prevention | Curiel, Clara, MD | University of Arizona | 75N91019D00013-0-759102000001-1 |
- Completed Projects
-
Jump to: Bladder | Breast | Cervix | Colon | Lung | Ovary | Pancreas | Prostate | Other Cancers
Cancer Type Project Type Project Title Application Principal Investigator (PI) Applicant PI's Institution NIH_RePORT_LINK Follow-on Project if Applicable (NIH_RePORT_LINK) Bladder Chemoprevention Evaluation of Agents/Protocols that Inhibit Two Major Pathways Involved in Human Urinary Bladder Cancer (PI3K, EGFR) and Protocols to Reduce Their Toxicity Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201500036I-0-26100002-1 Chemoprevention Prevention of Urinary Bladder Cancer with Two Clinically-Ready Agents (Everolimus and Naproxen) When Administered in Combination Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201500036I-0-26100008-1 75N91019D00020-0-759102000003-1 Chemoprevention Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention of Urinary Bladder Cancers Grubbs, Clinton J., PhD University of Alabama at Birmingham 75N91019D00019-0-759101900130-1 75N91019D00020-0-759102000005-1 Immunoprevention Multi-antigen Vaccines for the Primary and Secondary Prevention of Bladder Cancer Disis, Mary (Nora) L., MD, MS University of Washington 261201500036I-0-26100006-1 261201500036I-0-26100011-1 Breast Biomarker Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventive Agents Employing Both High Risk (But Histologically Normal) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers Grubbs, Clinton J., PhD University of Alabama at Birmingham NA Biomarker Blood-based Biomarkers of Obesity-Induced Breast Inflammation Dannenberg, Andrew J., MD Weill Cornell Medicine 261201200018I-0-26100003-1 Chemoprevention Large Scale Synthesis of 9-cis-UAB30 to Support Translational Development of this Novel Chemopreventive Rexinoid Muccio, Donald D., PhD University of Alabama at Birmingham NA Chemoprevention Evaluation of GLG-302, a STAT3 Antagonist, in the Prevention of Mammary Cancer Lovell, Michael W., PhD GLG Pharma, LLC 261201200021I-0-26100004-1 261201500036I-0-26100003-1 Chemoprevention Evaluation of the Cancer Prevention Efficacy of GLG-302 Lovell, Michael W., PhD GLG Pharma, LLC 261201500036I-0-26100003-1 261201500036I-0-26100007-1 Chemoprevention Evaluation of STAT3 Antagonists in the Prevention of Mammary Cancer Lovell, Michael W., PhD GLG Pharma, LLC 261201500036I-0-26100007-1 Chemoprevention Efficacy of Metformin in the Methylnitrosourea-induced Model of ER+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201200021I-0-26100005-1 Chemoprevention Evaluation of the Prevention by ACTOPLUS/MET (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancers Occurring in Rodents on a High-Fat Diet Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201200021I-0-26100006-1 Chemoprevention Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201200021I-0-26100007-1 Chemoprevention Support for Endoxifen Gel Clinical Development Khan, Seema A., MD Northwestern University 261201500024I-0-26100002-1 Chemoprevention Examination of HJC0152 as a Putative Modulator of Glucose and Energy Metabolism for Mammary Cancer Shen, Qiang, MD, PhD MD Anderson Cancer Center 261201500018I-0-26100002-1 Chemoprevention Evaluation of “Clinical-Ready” Agents (Bazedoxifene and Lapatinib) in Combination for the Prevention of ER+ and ER- Mammary Cancers Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201500036I-0-26100005-1 Chemoprevention Targeted casein kinase 1δ (CK1δ) inhibition as a breast cancer prevention strategy Aldaz, C. Marcelo, MD, PhD MD Anderson Cancer Center 261201500018I-0-26100005-1 Chemoprevention Targeting the mTOR Pathway for the Prevention of Breast Cancer Brown, Powel H., MD, PhD MD Anderson Cancer Center 261201500018I-0-26100006-1 Immunoprevention Efficacy of a Multi-Antigen Vaccine in the Prevention of MNU-induced Mammary Cancers ER Positive in Female SD Rats Grubbs, Clinton J., PhD University of Alabama at Birmingham 261201200021I-0-26100002-1 Immunoprevention AAV1-Plac1 Vaccine Platform for Cancer Prevention Glazer, Robert I., PhD Georgetown University 261201200018I-0-26100002-1 Immunoprevention Development of a Multi-antigen, Multi-peptide Vaccine Based on Gene Expression Information to Prevent Triple Negative Breast Cancer (TNBC) in a Mouse Model You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100007-1 261201500037I-0-26100008-1 Immunoprevention Further Development of Multi-Antigen, Multi-Peptide Vaccine based on Gene Expression Information to Prevent Triple Negative Breast Cancer in a Mouse Model You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100008-1 Cervix Chemoprevention Nonclinical Safety, Toxicokinetic, and Stability Evaluation of Bio response Diindolylmethane Vaginal Cream for Topical Treatment of Cervical Intraepithelial Neoplasia (CIN) Zeligs, Michael, MD BioResponse, LLC 261201200025I-0-26100002-1 Immunoprevention Safety Evaluation of pNGVL4a-CRT-E6E7L2 (detox) Recombinant DNA Vaccine in Mice Roden, Richard B. S., PhD Johns Hopkins 261201200026I-0-26100002-1 Immunoprevention Support for HPV16L1/RG1 Chimeric Virus-Like Particle Vaccine Clinical Development Kirnbauer, Reinhard, MD Medical University Vienna 261201500026I-0-26100002-1 Immunoprevention cGMP Re-Supply of HPV16L1/16RG1 Kirnbauer, Reinhard, MD Medical University Vienna 75N91019D00027-0-759102100001-1 Immunoprevention cGMP Production of a Chimeric Virus-Like Particle Vaccine (RG1-VLP) for Prevention of HPV-Associated Cancers Kirnbauer, Reinhard, MD Medical University Vienna NA Colon Biomarker Effect of a Chemopreventive Agent on the Fecal Metabolite Profile in Intestinal Neoplasia Gross, Steven, PhD Cornell University NA Biomarker Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic Trials Bernard, Philip S., MD University of Utah 261201200013I-0-26100008-1 Chemoprevention Preclinical Development of mPGES-1 and 5-LOX Selective Inhibitors for Chemoprevention Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200020I-0-26100004-1 261201500024I-0-26100005-1 Chemoprevention Efficacy of Aspirin and Naproxen (Short-term Frequent Dosing) in Colorectal Cancer Models Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200020I-0-26100002-1 Chemoprevention Combination of Aspirin and Omeprazole for Colorectal Cancer Chemoprevention Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200020I-0-26100003-1 Chemoprevention NSAID Chemoprevention in Colorectal Cancer Fishel, Richard, PhD Ohio State University 261201200020I-0-26100005-1 Chemoprevention Efficacy of Eldecalcitol (ED-71) in Colorectal Cancer Prevention in ApcMin Mouse Model Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200015I-0-26100005-1 Chemoprevention Combination of Aspirin or Naproxen with Omeprazole for Colorectal Cancer Chemoprevention with Clinically Relevant Doses Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201500038I-0-26100003-1 Chemoprevention Prevention of Colorectal Cancer by ONC201 El-Deiry, Wafik, MD, PhD, FACP Fox Chase Cancer Center 261201500038I-0-26100006-1 Chemoprevention Determination of Dosing Regimens of Erlotinib in Combination with Sulindac for Prevention of Colorectal Cancer While Reducing Agent Toxicity. Dashwood, Roderick H., PhD, MS Texas A&M University 261201500018I-0-26100004-1 75N91019D00021-0-759101900130-1 Chemoprevention Chemoprevention of Colorectal Cancer with Olmesartan Medoxomil Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201500038I-0-26100011-2 Chemoprevention Optimization of Dosing Regimens of Sulindac in Combination with Erlotinib for Small Intestinal and Colon Cancer Prevention Dashwood, Roderick H., PhD, MS Texas A&M University 75N91019D00021-0-759101900130-1 Immunoprevention Characterization of Potential Antigens for Immunization Against Colon Cancer and Testing Multivalent Tumor Vaccines in Min Mice Broussard, Elizabeth, MD University of Washington 261201200013I-0-26100003-1 Immunoprevention Testing of Combination Immuno- and Chemoprevention Strategies for Lynch Syndrome Lipkin, Steven M., MD, PhD, FACMG Weill Cornell Medicine 261201500039I-0-26100003-1 261201500039I-0-26100005-1 Immunoprevention Immunogenic effects of NSAIDs with and without a vaccine in colon cancer prevention Disis, Mary (Nora) L., MD, MS University of Washington 261201500036I-0-26100004-1 75N91019D00019-0-759101900131-1 Lung Biomarker Modulation of Cigarette Smoke-induced Alterations in microRNA Expression and Lung Tumors in Mice Treated with Aspirin and Naproxen De Flora, Silvio, MD University of Genoa 261201200015I-0-26100003-1 261201200015I-0-26100006-1 Biomarker Effects of Chemopreventive Agents on Biomarkers Related to Lung Tumorigenesis: Alterations in Normal Lung, “At Risk” Histologically Normal Lung and Lung Lesions You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201200015I-0-26100004-1 Biomarker Examination of Exosomal miRNAs as Potential Biomarkers for Chemopreventive Efficacy in Mouse Models of Lung Squamous Cell Carcinoma You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100003-1 Biomarker Modulation of miRNA Expression in Blood or Other Biological Fluids Compared with Tissue Levels in Mice Exposed to Cigarette Smoke and/or with NSAIDs Izzotti, Alberto, MD, PhD University of Genoa 261201200015I-0-26100006-1 Chemoprevention In Vivo Evaluation of a Chemopreventive Agent, Ciclesonide, in Mouse Lung Tumor Model by Inhalation Sharma, Sheela, PhD, MS Integrated Laboratory Systems, Inc. 261201200013I-0-26100002-1 Chemoprevention Anti-inflammatory Effects of Fixed Dose Combination of Pioglitazone and Metformin for Lung Cancer Prevention Wattenberg, Lee W., MD University of Minnesota 261201200015I-0-26100002-1 Chemoprevention Effects of Weekly or Intermittent Dosing Regimens of EGFR, MEK and PI3K Inhibitors in Mouse Models of Lung Cancer Wang, Yian, MD, PhD Washington University at St. Louis 261201200013I-0-26100007-2 Chemoprevention Chemoprevention with Aerosolized Bexarotene in Mouse Models of All Three Major Subtypes of Lung Cancer: Adenocarcinoma, Squamous Cell Carcinoma and Small Cell Lung Cancer Wang, Yian, MD, PhD Medical College of Wisconsin Cancer Center 261201200020I-0-26100007-1 261201500024I-0-26100004-1 Chemoprevention Support for Aerosol Development of Bexarotene Wang, Yian, MD, PhD Medical College of Wisconsin Cancer Center 261201500024I-0-26100004-1 Chemoprevention Lung Cancer Chemoprevention by microRNA Delivery Izzotti, Alberto, MD, PhD University of Genoa 261201500037I-0-26100005-1 75N91019D00020-0-759101900130-1 Immunoprevention Use of TERT Vaccine in Prevention of Lung Cancer in Animal Models You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201200013I-0-26100006-1 261201500037I-0-26100002-1 Immunoprevention Multi-Antigen Vaccine for Lung Cancer Prevention Disis, Mary (Nora) L., MD, MS University of Washington 261201200013I-0-26100009-1 Immunoprevention Development of Multiantigen Vaccines to Prevent the Development of Lung Adenocarcinomas Driven by either K-RAS or EGFR Oncoproteins in Mice You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100002-1 75N91019D00020-0-759102000002-1 Immunoprevention Rational Design and Development of a Multi-Antigen Multi-Peptide Vaccine Based on Genomic Information to Prevent Lung Cancer Initiation and Progression You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100004-1 Ovary Chemoprevention Ovarian Cancer Chemoprevention Benbrook, Doris M., PhD University of Oklahoma Health Sciences 261201500038I-0-26100002-1 Chemoprevention Ovarian Cancer Chemoprevention Benbrook, Doris M., PhD University of Oklahoma Health Sciences 261201500041I-0-26100002-1 Immunoprevention Mesothelin Vaccination for the Prevention of Ovarian Cancer Scholler, Nathalie, MD, PhD SRI International 261201200014I-0-26100002-1 261201500041I-0-26100003-1 Immunoprevention Optimization and Further Development of Mesothelin Vaccine for the Prevention of Ovarian Cancer Scholler, Nathalie, MD, PhD SRI International 261201500041I-0-26100003-1 Pancreas Chemoprevention Targeting P2X7 Receptor Antagonists for Prevention of Pancreatic Cancer Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200013I-0-26100004-1 Chemoprevention Targeting CCK2R for Pancreatic Cancer Prevention Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200020I-0-26100006-1 Chemoprevention Preclinical Studies to Evaluate the Combination of Metformin and Aspirin for the Prevention of Pancreatic Cancer Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200013I-0-26100010-1 Chemoprevention Optimization of GEM Models for High-Risk Cohorts of Human Pancreatic Cystadenomas, IPMNs and PanINs Progression to PDAC Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201500038I-0-26100004-1 Immunoprevention Development of Muc1 Vaccine for the Prevention of Pancreatic Cancer Rao, Chinthalapally V., PhD University of Oklahoma Health Sciences 261201200013I-0-26100005-1 Immunoprevention Cancer Prevention by α-Enolase Vaccination Novelli, Francesco, MD University of Turin 261201500018I-0-26100003-1 Immunoprevention Effect of a Multipeptide KRAS Vaccine in the Prevention of Pancreatic Cancer Driven by KRAS Oncoprotein You, Ming, MD, PhD Medical College of Wisconsin Cancer Center 261201500037I-0-26100006-1 75N91019D00020-0-759102000001-1 Prostate Chemoprevention Chemoprevention of Prostate Cancer via Estrogen Receptor β Agonists McCormick, David L., PhD, DABT IIT Research Institute 261201200016I-0-26100003-1 Chemoprevention Novel Androgen Receptor Antagonist-Mediated Chemoprevention of Prostate Cancer in Preclinical Model McCormick, David L., PhD, DABT IIT Research Institute 261201500042I-0-26100002-1 Chemoprevention Preclinical Evaluation of a New Lipid-Based SMEDDS BR-9001 Formulation Zeligs, Michael, MD BioResponse, LLC 261201500024I-0-26100003-1 261201500042I-0-26100003-1 Chemoprevention Preclinical Development of Chemopreventive agent 4-methylumbelliferone: Formulation Optimization Lokeshwar, Vinata, PhD Augusta University NA 261201500036I-0-26100010-1 Chemoprevention Prostate Cancer Prevention by Aspirin and/or Other NSAIDs Bosland, Maarten C., DVS, PhD University of Illinois 261201500038I-0-26100005-1 Chemoprevention Preclinical Efficacy Evaluation of The Lipid-Based SMEDDS Formulation of DIM, BR-9001 Zeligs, Michael, MD BioResponse, LLC 261201500042I-0-26100003-1 Other, Endometrial Chemoprevention cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials Benbrook, Doris M., PhD University of Oklahoma Health Sciences NA Chemoprevention Chemoprevention of Endometrial Hyperplasia and its Transition to Endometrial Cancer with NSC 721689 Benbrook, Doris M., PhD University of Oklahoma Health Sciences 261201500038I-0-26100008-1 Other, Esophagus Chemoprevention Chemoprevention of Esophageal Cancer by Targeting Multiple Pathways in a Mouse Model of Barrett’s Esophagus Wang, Timothy C., MD Columbia University 261201500039I-0-26100002-1 Other, Liver Chemoprevention Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH) Beretta, Laura, PhD MD Anderson Cancer Center 261201500018I-0-26100007-1 Other, Oral/Head And Neck Chemoprevention Oral Cancer Chemoprevention by Inhibitors of Inducible Nitric Oxide Synthase (iNOS) McCormick, David L., PhD, DABT IIT Research Institute 261201200016I-0-26100002-1 Other, Solid Tumors Immunoprevention A Polyvalent Vaccine Against Fusion Proteins Observed in Solid Tumors Jaffee, Elizabeth M., MD Johns Hopkins Kimmel Cancer Center 261201200018I-0-26100006-1 Other Chemoprevention Targeting the IL-6 Signaling Pathway as Chemopreventative Therapy for High-Risk Malignant Mesothelioma Populations Menges, Craig, PhD Fox Chase Cancer Center 261201500032I-0-26100002-1